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Introduction
The urinary tract infections (UTIs) caused by vari-
ous Candida spp. have been recognized by clinicians 
to be a growingly extensive and pervasive nosocomial 
issue (Bukhary 2008). It has been estimated that Can­
dida spp. are in charge of about 10–15% of nosocomial 
UTIs (Alkilani et al. 2017). The presence of Candida 
in urine, a medical condition known as candiduria 
(Alkilani et al. 2017), if not correctly treated, might 
result in considerable morbidity and mortality rates 
(Goyal et al. 2016). Observational studies have par-
ticularized Candida albicans to be the most prevalent 
etiologic agent detected in more than 51% of candiduria 
cases, followed by Candida glabrata as well as Candida 
tropicalis (Bukhary 2008). Many risk factors predispose 
to the occurrence of candiduria, for instance, immu-
nosuppressive therapy, extremes of age, underlying 
genitourinary abnormality, female sex, prior surgeries, 
indwelling urinary catheters, diabetes mellitus, recent 
use of broad-spectrum antibiotics, as well as the pro-
longed hospital stay (Bukhary 2008; Alhussaini et al. 
2013; Hassaneen et al. 2014).
In Egypt, the contribution of Candida spp. to UTIs 
is alarmingly increasing reflecting a problem that might 
be described as nationwide. In Alexandria, located on 
the Mediterranean coast in North Egypt, a study meas-
uring the incidence rate of catheter-associated urinary 
tract infections (CAUTIs) in four intensive care units 
(ICUs) in Alexandria University hospitals from 2007 to 
2008 encountered Candida spp. in 51% of the examined 
urine cultures (Talaat et al. 2010). In the capital and 
southern governorates, 20% of renal failure patients vis-
iting the University hospitals of Cairo, Assiut and Sohag 
in 2012 were suffering from candiduria (Alhussaini 
et al. 2013). In the eastern part of the Nile delta, a study 
conducted on 300 hospitalized patients in Zagazig 
Univer sity hospitals, from 2012 to 2013, revealed a can-
diduria prevalence of 14% in these patients (Hassaneen 
et al. 2014). The situation in Menofia, another Delta 
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The contribution of fluconazole-resistant Candida spp. isolates to urinary tract infections in Egypt has become a nationwide problem. 
A recent approach to overcome such disaster is combining conventional antifungals with non-antifungals. This study investigated the inter-
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was applied to assess the amikacin effect on the expression of the efflux pump genes MDR1, CDR1, and CDR2. The downregulatory effect 
of amikacin on the expression of the studied genes caused a percentage of reduction in the expression level ranging between 42.1 and 94%. 
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governorate, was almost similar where candiduria 
infec tion was reported among 19% of catheterized 
ICU patients in its University hospitals, from 2013 to 
2014 (Alkilani et al. 2017). As the resistance of differ-
ent Candida spp. towards different antifungal agents 
is proceeding to develop and expand, new treatment 
trends are extensively necessitated (Spampinato and 
Leonardi 2013). Unfortunately, developing novel anti-
fungal agents is an extremely complicated and difficult 
task. Thus, an alternative approach nowadays focuses 
on the combina tion of conventional antifungal agents 
with non-antifungals (Lu et al. 2018).
Aminoglycosides are natural or semisynthetic anti-
microbials and are one of the first agents to be used 
for routine clinical practice (Krause et al. 2016). They 
are bactericidal agents exerting their effect during the 
translation process through the interference with the 
correct decoding of the mRNA (Chiem et al. 2016). 
They are active against Gram-negative bacteria like 
Pseudomonas spp., members of the Enterobacteriaceae 
family, and could be combined with beta-lactams to 
treat Gram-positives infections (Chiem et al. 2016). 
Amikacin is the most widely used semisynthetic amino-
glycoside that can be used alone or with other antibiot-
ics to treat infections caused by aerobic Gram-negative 
bacteria, Nocardia species, and Mycobacterium tuber­
culosis, and has a particular significance in the treat-
ment of several life-threatening infections disseminated 
among neonates (Ramirez and Tolmasky 2017).
Over the past decades, substantial attempts have 
been made to explore novel antimicrobial activities of 
aminoglycosides, for example, their antifungal effect 
(Lu et al. 2018). However, until now, the data concern-
ing the enhancement of conventional antifungal agents’ 
activity in combination with amikacin against Candida 
spp. has not been reported.
The current study aimed at the investigation of the 
activity of amikacin against Candida spp. isolates caus-
ing UTIs in the patients admitted to the Alexandria 
Main University Hospital (AMUH) in Egypt. It also 
focused on elucidating the role of amikacin as a resist-
ance-modifying agent that might help in increasing the 
susceptibility of resistant strains to one of the most fre-
quently used antifungal agents, fluconazole. Moreover, 
the underlying mechanisms of amikacin sensitization 
of Candida isolates to fluconazole were studied.
Experimental
Materials and Methods
Clinical isolates and culture conditions. Twenty-
eight non-replicated clinical isolates of Candida spp. 
were collected from the urine culture of patients sub-
mitted to “AMUH” through the hospital’s routine 
laboratory facility during October 2018. These isolates 
were numbered from C1 to C28. In addition, the stand-
ard strain of C. albicans ATCC 231GI was included 
in this study.
All isolates were preserved as frozen stocks in 15% 
glycerol at –20°C. A fresh culture was obtained by 
subculturing the isolates on Sabouraud dextrose agar 
(SDA) (LAB M, UK) for 48 h at 37°C before use.
Antimicrobial agents. Amikacin (Advomikacin® 
500 mg/2 ml, Advocure, Egypt) was purchased from 
community pharmacies, while fluconazole was obtained 
from Sigma  Aldrich, USA. Stock solutions of both 
amikacin and fluconazole were prepared in sterile dis-
tilled water.
Identification of Candida spp. isolates to the spe-
cies level. The Tween 80 opacity test. For the prepa-
ration of the Tween 80 opacity test medium, 10 g of 
bacteriological peptone (LAB M, UK), 0.1 g of CaCl2, 
5 g of NaCl, and 15 g of agar were added to 1,000 ml 
of distilled water. After autoclaving, the medium was 
allowed to cool to approximately 50°C; then, 5 ml of 
previously autoclaved Tween 80 (Guangzhou Jinhuada 
Chemical Reagent Co., China) was added. Few colo-
nies of an overnight culture of each of the tested iso-
lates grown on SDA were subcultured to the Tween 
80 opacity test medium, using sterile cotton swabs, to 
form an inoculation site of about 10 mm in diameter. 
The plates were incubated for up to 10 days at 37°C. 
The isolates tested were inoculated in duplicate. The 
detection of a halo around the site of the inoculation 
was recognized as a positive result that indicated the 
capability of Candida isolates to produce an esterase 
(Aktas et al. 2002).
Germ tube formation test. Two or three colonies of 
each of the isolates tested were inoculated into 0.5 ml 
of sterile trypticase soy broth (HIMEDIA, India), dis-
pensed in a sterile Eppendorf, and then, incubated at 
37°C for 2–3 hours. After incubation, few drops of the 
suspension were transferred to a clean microscopic slide 
for examination under a magnification of 100 × for the 
detection of germ tube (Deorukhkar et al. 2012). A pos-
itive control (C. albicans ATCC 231GI) was included in 
the experiment.
Identification of non-albicans Candida isolates 
using the Vitek-2 system. The Vitek-2 system (Kaur 
et al. 2016) (Vitek® 2 Compact, BioMerieux, France) was 
used to confirm the identity of the non-albicans Candida 
isolates according to the manufacturer’s instructions.
Determination of virulence determinants among 
Candida spp. isolates. Biofilm formation. Biofilm 
formation was assayed according to Pongracz et al. 
(2016) with some modifications. Candida spp. isolates 
were grown on SDA plates at 37°C for 24 h. A  sus-
pension of each isolate at a density of 2 × 106 cells/ml 
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was prepared in sterile saline. Then, 100 µl of the cell 
suspension was placed in each well containing 100 µl 
of sterile double strength RPMI 1640 medium (Sigma 
Aldrich, USA) buffered with morpholine propane sul-
fonic acid (MOPS) (Sigma Aldrich, USA). After 48 h 
incubation at 37°C, the planktonic cells were discarded 
and the wells were properly washed twice with saline. 
Biofilms were stained with 100 µl of crystal violet dye 
(0.2%) for about 15 min. The excess dye was washed 
and 100 µl of ethanol was added to each well to solubi-
lize the bound dye (Pongracz et al. 2016). The absorb-
ance was measured at 630 nm. Each isolate was tested 
in triplicate. The optical density of each strain (ODs) 
was calculated as the mean value of the absorbance 
of 3 wells and this value was then compared with the 
absorbance of negative control (ODnc) (containing 
100 µl of saline instead of bacterial inoculum). The 
results were interpreted as follows: strong biofilm for-
mation (4 ODnc < ODs), moderate biofilm formation 
(2  ODnc < ODs ≤ 4 ODnc), weak biofilm formation 
(ODnc < ODs ≤ 2 ODnc) and no biofilm formation 
(ODs ≤ ODnc) (Rodrigues et al. 2010).
Production of proteinase enzymes. The produc-
tion of proteinase enzymes was detected using bovine 
serum albumin medium (2% dextrose, 0.05% MgSO4, 
0.1% KH2PO4 and agar 2% mixed after autoclav-
ing and cooling to 50°C with bovine serum albumin 
(MP Biomedicals, USA) at a  concentration of 1%). 
Aliquots of 20 µl of each of the Candida isolate’s sus-
pension (at a density of 108 cells/ml) were inoculated 
into previously punched cups in the serum medium. 
The plates were incubated for six days at 37°C. The pre-
cipitation zone (Pz) value was calculated as the ratio 
of the diameter of the cup to the total diameter of the 
cup plus the precipitation zone. The results express-
ing the enzymatic activity were interpreted as follows: 
Pz value = 1 (negative); Pz value = 0.75 – 0.9 (low pro-
ducers); Pz  value = 0.51 – 0.74 (moderate producers); 
and Pz value = 0.35 – 0.5 (high producers). The test was 
performed in duplicate and the average of two meas-
urements was recorded (Mohan Das and Ballal 2008; 
Mattei et al. 2013).
Production of the phospholipase enzyme. Pho- 
 spho lipase activity was tested using egg yolk agar me - 
dium consisting of SDA, 0.005 mol CaCl2, 1 mol NaCl 
and 8% sterile egg yolk emulsion (HIMEDIA, India). 
The egg yolk emulsion was centrifuged; the supernatant 
was completed to its initial volume with sterile distilled 
water and added to the sterilized medium (Fotedar and 
Al-Hedaithy 2005). Aliquots of 20 µl of each of the Can­
dida isolate’s suspensions (at a density of 106 cells/ml) 
were inoculated into previously punched wells in the 
solid medium. The plates were incubated for 48 h at 
37°C. The results expressing the enzyme activity were 
interpreted as follows: Pz = 1 (no enzyme activity), 
0.63 < Pz < 1.0 (moderate enzyme activity), and Pz < 0.63 
(strong enzymatic activity) (Wiebusch et al. 2017).
Determination of the minimum inhibitory con-
centrations (MICs) of fluconazole and amikacin 
against Candida spp. isolates. The MICs of both ami-
kacin and fluconazole against all the isolates tested 
were determined by the broth microdilution method 
using RPMI buffered with MOPS. For the preparation 
of a suitable inoculum, each isolate was subcultured on 
SDA plates and incubated at 37°C, and then, adjusted 
to 0.5 McFarland standard. A working suspension was 
prepared by a 1:100 dilution of the stock Candida iso-
late’s suspension (Schwalbe et al. 2007). The growth 
control and sterilized medium control wells were 
included in each experiment. MICs of fluconazole was 
defined as the concentration resulting in 50% growth 
inhibition, while MICs of amikacin was defined as the 
concentration resulting in 100% growth inhibition. 
Isolates with fluconazole MICs of ≥ 64 μg/ml were inter-
preted as resistant (CLSI 2008).
The antibiotic resistance-modifying activity of 
amikacin against fluconazole-resistant Candida clin-
ical isolates. To assess the role of amikacin as a resist-
ance-modifying agent against 12 fluconazole-resistant 
Candida clinical isolates, the MIC of fluconazole alone 
was compared to its MIC in the presence of 4,000 µg/ml 
of amikacin to test the capability of amikacin to sen-
sitize the Candida isolates resistant to fluconazole. 
Modulation factor (MF), calculated as MICfluconazole alone/ 
MICfluconazole + amikacin, was used to express the modulating 
effect of amikacin (Fankam et al. 2015).
Rhodamine efflux assay. A rhodamine efflux assay 
was performed according to Lu et al. (2018) with minor 
modifications. This assay was conducted to determine 
whether amikacin affected the efflux pump activity in 
three fluconazole-resistant Candida spp. isolates: C6, 
C8, and C21. Briefly, each of the selected isolates was 
subcultured on SDA plates. A loopful from each isolate 
culture was subcultured in yeast extract-peptone-dex-
trose (YPD) broth and incubated overnight at 35°C in 
a shaking incubator at 200 rpm. The overnight culture 
was collected into a sterile falcon, washed with glu-
cose-free PBS and the concentration was adjusted to 
1 × 107 CFU/ml. Next, the ethanolic rhodamine solution 
(Rhodamine B, Loba Chemie, India) was added to the 
cell suspension to reach a final concentration of 10 µM. 
The culture was incubated with rhodamine at 37°C for 
50 min, followed by incubation on an ice water-bath 
for 10 min. Cells were collected, washed properly with 
glucose-free PBS and resuspended in glucose/PBS 
(5%). Amikacin was added to a final concentration of 
4,000 µg/ml and, at the same time, the rhodamine-alone 
group (containing no amikacin) served as a  control 
group. The fluorescence intensity of the extracellular 
rhodamine was recorded every 30 min, at time intervals 
Edward E.A. et al. 176
of 0, 30, 60, 90 and 120 min, using a spectrofluorom-
eter (Shimadzu, Japan) with excitation at 485 nm and 
emission at 530 nm. All results were represented as an 
average of three biological samples.
Molecular quantification of the Candida efflux 
pump genes MDR1, CDR1, and CDR2 using quan-
titative real-time PCR. Quantitative real-time PCR 
was applied for two isolates C6 and C21 whose efflux 
pump activity was more prominently affected by ami-
kacin using the Applied Biosystems 7500 Real-Time 
PCR System (Thermo Fisher Scientific Inc., USA). This 
was employed to assess the localized expression of the 
MDR1 (multidrug resistance 1), CDR1 (Candida drug-
resistant 1), and CDR2 (Candida drug-resistant 2) genes 
before and after 48-hour treatment with 4,000 µg/ml of 
amikacin. The data were normalized against the house-
keeping gene ACT1. Gene-specific primer pairs were 
synthesized in Willowfort, UK, relying on the previ-
ously published sequences (Chau et al. 2004). The prim-
ers of the ACT1, MDR1, CDR1, and CDR2 genes for the 
RT-PCR amplification of cDNA are shown in Table I.
RNA isolation and reverse transcription. For both 
selected isolates, the total RNA was extracted, according 
to the manufacturer’s instructions, from the overnight 
subculture using the TRIzol® MaxTM Bacterial RNA 
Isolation Kit (Ambion by Life Technologies). Then, the 
quantification of RNA was carried out using Jenway 
Genova Nano, Keison Products, UK.
Using the TOPrealTM One step RT qPCR Kit (Enzy-
nomics), the step of reverse transcription was accom-
plished. The composition of the real-time PCR mixture 
was as follows: 1 µl of TOPrealTM One step RT qPCR 
Enzyme Mix, 10 µl of 2X TOPrealTM One step RT qPCR 
Reaction Mix, 1 µl of each primer, 1 μl of total RNA, 
and sterile DNase-free water to reach to a total reaction 
volume of 20 μl.
After applying a preliminary holding step at 50°C 
for 30 min, the cycling conditions for the PCR reaction 
were as follows: an initial denaturation step at 95°C for 
10 min, then 40 cycles of denaturation at 95°C for 5 sec, 
followed by annealing/extension at 60°C for 30 sec. In 
every RT-PCR run, negative control containing sterile 
DNase-free water instead of the RNA template was 
involved. Samples were tested in triplicate.
To ensure the absence of the primer-dimers or any 
other artifacts, analysis of the melting curves was done 
in one cycle of 94°C, 53°C and 94°C, one minute each. 
The amplification curves, as well as the values of the 
cycle threshold (Ct) were established using the Strata-
gene MX3005P software.
The levels of the expression of each of the MDR1, 
CDR1 and CDR2 genes were normalized to the expres-
sion level of the house keeping gene ACT1 and com-
pared to the corresponding expression levels in the 
control untreated isolates. For the calculation of the 
transcripts of each of the target genes, the Pfaffl method 
or ΔΔCt method was applied (Pfaffl 2001).
Statistical analysis. Data were expressed as means 
± S.D. In the case of multi-variable comparisons, one-way 
ANOVA and Bonferroni testing were performed with 
the Prism 3 GraphPad software. Differences were rec-
ognized to be significant at p-value < 0.05. The included 
data were the mean of three biological replicates.
Results
Demographic profile of candiduric patients. The 
demographic characteristics of 28 candiduric patients 
included in this study are shown in Table II. Infection 
with C. albicans isolates was more prevalent in males 
(61.1%) when compared to females (38.9%). However, 
the incidence of non-albicans Candida isolates was 
equally detected in both sexes. The frequency of both 
C. albicans and non-albicans isolates was higher among 
elderly patients (61 – > 70 years) in comparison with 
younger adults, and showed a focused predominance 
in patients reaching extremes of age (61.1, and 50%, 
respectively).
Identification of Candida spp. isolates. The applied 
phenotypic tests (the germ tube formation and the 
Tween 80 opacity test), as well as the Vitek-2 system, 
segregated the Candida isolates tested into: 18 C. al bi­
cans, 7 C. glabrata, 2 C. tropicalis, and 1 C. famata 
(Table III; Fig. S1).
ACT1 F TTGGTGATGAAGCCCAATCC Chau et al. 2004
 R CATATCGTCCCAGTTGGAAACA 
MDR1
 F TTACCTGAAACTTTTGGCAAAACA 
Chau et al. 2004
 R ACTTGTGATTCTGTCGTTACCG 
CDR1
 F TTTAGCCAGAACTTTCACTCATGATT 
Chau et al. 2004
 R TATTTATTTCTTCATGTTCATATGGATTGA 
CDR2
 F GGTATTGGCTGGTCCTAATGTGA 
Chau et al. 2004
 R GCTTGAATCAAATAAGTGAATGGATTAC
Table I
Sequences of primers for the genes selected for transcript analysis using quantitative RT-PCR.
Gene Sequence (5’–3’) ReferenceOrientation
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Candida albicans (n = 18) 11 61.1  7 38.9 0  0 6 33.3 1  5.6 11 61.1
Non-albicans Candida isolates (n = 10)  5 50  5 50 1 10 3 30 1 10  5 50
Total (n = 28) 16 57.1 12 42.9 1  3.6 9 32.1 2  7.1 16 57.1
Table II
Demographic profile of candiduric patients.
Demographic variables
Sex Age group (years)
Male Female 61– > 7051–6041–5030–40
n % n % n % n % n % n %
C1 C. tropicalis Strong 0.26 0.33 128
C2 C. albicans Strong 0.4 0.48 16
C3 C. albicans Strong 0.16 0.29 8
C4 C. albicans Strong 0.19 0.29 32
C5 C. albicans Strong 0.2 1 8
C6 C. albicans Strong 0.2 0.3 1024
C7 C. tropicalis Strong 0.22 0.23 128
C8 C. glabrata Weak 0.18 0.21 1024
C9 C. glabrata Weak 0.67 0.22 1024
C10 C. glabrata Moderate 0.5 0.2 32
C11 C. albicans Strong 0.26 0.26 16
C12 C. glabrata Moderate 0.43 0.23 32
C13 C. albicans Strong 0.4 0.2 8
C14 C. albicans Strong 0.26 0.3 256
C15 C. albicans Strong 0.24 0.24 16
C16 C. albicans Strong 0.24 0.24 8
C17 C. albicans Strong 0.15 0.27 1024
C18 C. glabrata Moderate 0.25 0.21 8
C19 C. albicans Weak 0.15 0.67 2
C20 C. albicans Strong 0.14 0.31 1024
C21 C. albicans Strong 0.17 0.4 1024
C22 C. albicans Weak 0.15 0.39 1
C23 C. albicans Strong 0.18 0.32 1024
C24 C. albicans Strong 0.17 0.41 8
C25 C. glabrata Weak 0.17 0.23 8
C26 C. glabrata Moderate 0.2 0.16 256
C27 C. albicans Strong 0.16 0.32 16
C28 C. famata Strong 0.16 0.4 128
Table III
Identification, virulence determinants, and the minimum inhibitory concentration (MIC)
of fluconazole against the Candida spp. isolates tested.
a The Pz (precipitation zone) value: 1 (negative), 0.75–0.9 (low producers),
 0.51–0.74 (moderate producers) and 0.35–0.5 (high producers)
b The Pz value: 1 (negative), < 1 – > 0.63 (moderate), and < 0.63 (strong)
c CLSI breakpoint for fluconazole is 64 μg/ml
Isolate
code
Candida
species
Virulence determinants
MIC
of Fluconazole
(µg/ml)c
Biofilm
formation
Proteases
production
Pz valuea
Phospholipase
production
Pz valueb
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Determination of the MIC of fluconazole against 
Candida spp. isolates. Among Candida isolates, 12 iso-
lates (42.9%) were resistant to fluconazole with MICs 
ranging from 128 to 1,024 µg/ml. The percentage of the 
resistant non-albicans Candida spp. isolates reached 
about 60% when compared to fluconazole-resistant 
C. albi cans (33%). About 43% of C. glabrata isolates were 
resistant to fluconazole. Both isolated strains of C. tropi­
calis were resistant to fluconazole, as well as a  single 
C. famata isolated strain in this study (Tables III and IV).
Relationship between the virulence determinants 
in Candida spp. isolates and their susceptibility to 
fluconazole. Out of the 28 tested isolates, 19 isolates 
(67.9%) were strong biofilm formers. Among these, 
three isolates (15.8%) were non-albicans Candida iso-
lates (2 C. tropicalis, and 1 C. famata) that showed resist-
ance to fluconazole (MIC = 128 µg/ml). The remaining 
16  strong biofilm formers (84.2%) were C. albicans, 
out of which six isolates were resistant to fluconazole 
(MICs ranging from 256 to 1,024 µg/ml). The moderate 
biofilm formation was detected among four C. glabrata 
isolates, where only one of these was resistant to flu-
conazole (MIC = 256 µg/ml). Five isolates (17.9% of 
the total number of the isolates tested) were defined as 
weak biofilm formers, and this group comprised two 
fluconazole-susceptible C. albicans, one fluconazole-
susceptible C. glabrata, and two fluconazole-resistant 
C. glabrata isolates (MIC = 1,024 µg/ml) (Table III).
Production of proteinase enzymes was high among 
27 isolates (96.4% of the tested isolates), among which 
11  isolates (40.7%) were resistant to fluconazole. 
These high producers of proteinases were classified as 
18 C. albicans and nine non-albicans Candida isolates. 
Only one C. glabrata isolate showed moderate produc-
tion of proteinases, however, it was resistant to flucona-
zole (MIC = 1,024 µg/ml) (Table III).
A total of 26/28 isolates (92.9%) were strong produc-
ers of phospholipase, out of which 12 isolates (46.2%) 
were resistant to fluconazole. One isolate was a mod-
erate producer, while the second showed a negative 
result for phospholipase production. Both isolates were 
fluconazole-susceptible C. albicans (Table III; Fig. S2).
Determination of the MIC of amikacin against 
Candida spp. Isolates. The MIC of amikacin deter-
mined by the broth microtiter dilution method was 
> 4,096 against 27 isolates (96.4 % of the tested isolates), 
while isolate C28 had a MIC of 2,048 µg/ml.
The antibiotic-resistance modifying activity of 
amikacin against fluconazole-resistant Candida clini-
cal isolates. The antibiotic-resistance modifying activity 
of amikacin (4,000 µg/ml) was tested against 12 flucona-
zole-resistant Candida clinical isolates. As illustrated in 
Table V, amikacin potentially sensitized the antimicro-
bial activity of fluconazole against 11 tested isolates with 
an MF ranging between 32 and 256. The MF calculated 
for the majority of fluconazole-resistant C. albicans iso-
lates (with exception of one strain showing an MF of 64) 
reached very high values equivalent to 256. The MIC 
of fluconazole was reduced by 32-fold in the presence 
of 4,000 µg/ml of amikacin when tested against flucon-
azole-resistant isolates of C. tropicalis, C. glabrata, and 
C. famata. A single isolate of C. glabrata, C26, was not 
sensitized to fluconazole in the presence of amikacin.
Rhodamine efflux assay. To illustrate the mecha-
nism of amikacin sensitization to fluconazole, the efflux 
pump activity of two C. albicans isolates C6 and C21, as 
well as one C. glabrata, C8, was studied in the absence 
and presence of amikacin (4,000 µg/ml) using the rho-
damine efflux assay (Fig. 1–3). Both C. albicans isolates, 
C6 and C21, showed a decline in the fluorescence inten-
sity with percentages of reduction varying over time. 
The fluorescence intensity dropped promptly during the 
first 30 and 60 minutes of contact of isolate C6 with 
amikacin with percentages of reduction in the fluores-
cence intensity reaching 13.4 and 12.9%, respectively. 
After 90 and 120 minutes of treatment, those percent-
ages began to decrease although still being considerable 
(Fig. 1). The pattern of fluorescence intensity reduction 
for isolate C21 displayed dissimilarity over time, where 
the effect of amikacin on the efflux pump activity for 
Candida albicans (n = 18) 12 (66.7%) 6 (33.3%)  16 1024 1–1024
Non-albicans Candida isolates (n = 10)  4 (40%) 6 (60%) 128 1024 8–1024
Candida glabrata (n = 7)  4 (57.1%)a 3 (42.9%)  32 1024 8–1024
Candida tropicalis (n = 2)  0 (0%)a 2 (100%) 128b NDc ND
Candida famata (n = 1)  0 (0%)a 1 (100%) ND ND ND
Table IV
Fluconazole susceptibility of different Candida spp.
a The percentage was calculated relative to the total number of non-albicans Candida isolates collected in this study
b MIC50 is calculated here as the arithmetic mean of the MIC values for both Candida tropicalis strains
c ND – not determined
Candida species
Fluconazole susceptibility n (%)
MIC50 MIC90
MIC range
(µg/ml)S R
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the first 30 minutes was weak resulting in a percentage 
of reduction of merely 3.7%. However, a time-gradient 
remarkable effect was established and percentages of 
reduction in the fluorescence intensity reached 7.3, 
8.5, and 8.9% at 60, 90, and 120 minutes, respectively 
(Fig. 3). The isolate of C. glabrata, C8, didn’t show any 
prominent decrease in the fluorescence intensity for the 
amikacin-treated cells when compared to the control 
where the percentages of reduction in the fluorescence 
intensity over the tested time intervals ranged from 0.4 
to 1.5% (Fig. 3).
Comparing the effect of amikacin (4,000 µg/ml) on 
the efflux of rhodamine among the three tested isolates 
C6, C8, and C21 after 120 minutes of treatment, a sta-
tistically significant effect (p-value < 0.05) was observed 
for C6 and C21 with percentage of reduction in the fluo-
rescence intensity of 8.9% for both isolates. However, the 
effect of amikacin treatment was statistically non-signi-
ficant (p-value > 0.05) for isolate C8 where the percent-
age of reduction in the fluorescence intensity reached 
hardly 1.5% after 120 minutes of treatment (Fig. 4).
Molecular quantification of the Candida efflux 
pump genes MDR1, CDR1, and CDR2 using real-
time PCR. For two C. albicans isolates, C6 and C21, the 
effects of 48-hour treatment with 4,000 µg/ml amikacin 
on the expression of the Candida efflux pump genes 
MDR1, CDR1 and CDR2 was studied using the quan-
titative RT-PCR. Representative amplification curves 
and melting curve analysis for each of the housekeeping 
gene ACT1 and the three efflux pump genes MDR1, 
C1 C. tropicalis 128 4 32
C6 C. albicans 1024 4 256
C7 C. tropicalis 128 4 32
C8 C. glabrata 1024 32 32
C9 C. glabrata 1024 32 32
C14 C. albicans 256 4 64
C17 C. albicans 1024 4 256
C20 C. albicans 1024 4 256
C21 C. albicans 1024 4 256
C23 C. albicans 1024 4 256
C26 C. glabrata 256 256 1
C28 C. famata 128 4 32
Table V
Resistance-modulating effect of amikacin (4000 µg/ml) on fluconazole-resistant
Candida clinical isolates.
a Modulation factor (MF) was calculated as MICfluconazole alone/MICfluconazole + amikacin.
Isolate
code
Candida
species
MIC of
fluconazole
alone (µg/ml)
MIC of fluconazole
(µg/ml) in the presence
of amikacin
Modulation
factor
(MF)a
Fig. 1. Inhibitory effect of amikacin (4,000 µg/ml) on the efflux of 
rhodamine in fluconazole-resistant Candida albicans (C6).
Fig. 2. Inhibitory effect of amikacin (4,000 µg/ml) on the efflux of 
rhodamine in fluconazole-resistant Candida glabrata (C8).
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CDR1, and CDR2 for C6 isolate are provided in the 
supplementary material (Fig. S3A and S3B).
The downregulatory effect of amikacin on the expres-
sion of the efflux pump genes of isolate C6 was exerted 
most prominently on the gene CDR1, followed by the 
gene MDR1, and lastly on the gene CDR2 with percent-
ages of reduction in the level of expression equivalent to 
89.4, 61, and 42.1%, respectively. Amikacin treatment 
of isolate C21 resulted in a profound downregulatory 
effect of the gene CDR2 with a percentage of reduc-
tion in the level of expression equivalent to 94%. This 
was observed to a lower extent for the gene MDR1, the 
expression of which was reduced by 43.5%. Concerning 
the gene CDR1, it has not been originally detected in 
the control untreated isolate C21. A highly significant 
reduction in the expression levels of the target genes, 
with a  p-value of < 0.0001 compared to the control, 
was detected for both tested isolates C6 and C21. The 
relative gene expression levels of the efflux pump genes 
MDR1, CDR1, and CDR2 compared to control cells for 
isolates C6 and C21 are illustrated in Figures 5A and 
5B, respectively.
Discussion
Candida spp. are responsible for 10–15% of UTIs 
worldwide and are categorized as the fourth most com-
mon cause of UTIs, especially in hospitalized and ICU 
patients (Yashavanth et al. 2013). In Egypt, a study car-
ried out in Alexandria University Students Hospital, 
a hospital providing services to more than 50,000 peo-
ple per year, identified C. albicans to be the causative 
organism of 36.7% of UTI cases in 2005 (Sallam et al. 
2005). In AMUH in 2008, Candida spp. were isolated 
from 63  out of 161  patients with UTIs (Talaat et al. 
2010). In the current study, 28 Candida spp. isolates 
from the urine culture of patients admitted to AMUH 
with UTIs were subjected to species characterization 
using two phenotypic tests; the germ tube formation 
and the Tween  80 opacity tests. Non-albicans Can­
dida spp., the identity of which was confirmed by the 
automated Vitek-2 system (Fig. S1), were less preva-
lent (35.7%) than C. albicans that were encountered 
in 18  (64.3%) of total isolates. Among non-albicans 
Candida isolates, C. glabrata was the most predomi-
nant (25%), followed by C. tropicalis (7.1%), and 
C. famata (3.6%), respectively (Table  III). Hassaneen 
et al. reported similar incidence rates of C. glabrata 
(21.4%) and C. tropicalis (7.1%) isolated from the 
urine of patients admitted with UTIs to the Zagazig 
University Hospitals in Egypt (Hassaneen et al. 2014). 
The situation in the Middle East seems to be analogous, 
and C. albicans was the most encountered in diabetic 
patients with candiduria in Arar, the northern area of 
Saudi Arabia, followed by C. glabrata, and C. tropicalis 
(Alenezy 2014). In Kuwait, C. albicans was the most 
prominent species recovered from urine cultures from 
candiduric patients in a tertiary care hospital (Alfouzan 
2015). Although non-albicans Candida spp. are emerg-
ing nowadays as potential pathogens responsible for 
candiduria (Kauffman 2005), C. albicans is still being 
reported as the dominant species infecting the urinary 
tract of not only Egyptian patients but also patients in 
several Arabic countries (Sallam et al. 2005; Bukhary 
2008; Omar et al. 2008; Alhussaini et al. 2013; Awad 
and Mohamad 2014; Alkilani et al. 2017). Demographi-
cally, in this study, a higher prevalence of candiduria 
was recorded in males (57.1%) as compared to females 
(42.9%) (Table II). Although females are known to be 
at a higher risk of developing candiduria owing to the 
frequent colonization of their vulvo-vestibular area 
with Candida spp. (Bukhary 2008), other observers 
found that it was more common in males (Jain et al. 
2011). This could be attributed to the involvement of 
other risk factors not approached in the current study. 
Older age is a classical risk factor for candiduria and 
the high incidence of cases observed at this age group 
(57%) (Table  II) is explained by the attenuated host 
defense mechanisms in patients reaching extremes of 
age. This finding is supported by the results of other 
researchers (Jain et al. 2011).
Aggravating the problem is the fact of the dissemi-
nation of resistance among urinary Candida spp. iso-
lates to different antifungal agents, especially to the 
azole group. Azoles, other than fluconazole, are poorly 
excreted in urine and, thus, are less effective in the 
treatment of candiduria (Alfouzan 2015). Therefore, the 
present study focused on determining the susceptibility 
of the tested isolates to fluconazole. Totally, 42.9% of the 
isolates tested were resistant to fluconazole. About 67% 
Fig. 3. Inhibitory effect of amikacin (4,000 µg/ml) on the efflux of 
rhodamine in fluconazole-resistant Candida albicans (C21).
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and 40% of C. albicans and non-albicans Candida spp., 
respectively, were susceptible to fluconazole (Tables III 
and IV). With the increased use of fluconazole, numer-
ous studies have become concerned with the emergence 
of fluconazole-resistant non-albicans Candida spp., 
especially C. tropicalis, which showed not only a better 
adaptation to the kidney but also possessed a reduced 
susceptibility to this azole (Kashid et al. 2012; Toner 
et al. 2016). Although the C. tropicalis prevalence was 
not high in this study (n = 2), both of the isolates were 
resistant to fluconazole (Tables III and IV).
The observed fluconazole resistance in Candida 
spp. and its relationship to the organism’s ability to 
shift from commensalism to pathogenesis has drawn 
an increasing attention in recent years because of 
resultant serious infections and failure of treatment 
(Mayer et al. 2013). This capability is attributable to 
various virulence determinants; adhesion to surfaces 
and secretion of extracellular hydrolases, proteinases 
and phospholipases are among these mechanisms of 
pathogenesis (Höfs et al. 2016). The majority of Can­
dida strains in this study were capable of producing 
proteinases and phospholipase (about 96 and 93%, 
respectively) (Table III; Fig. S2). A high rate of protein-
ases (91.4%) and a moderately high rate of phospholi-
pase (68.6%) production amongst C. albicans clinical 
isolates were reported earlier in the study conducted 
on 200 candiduric patients admitted to the ICU of the 
Theodor Bilharz Research Institute Hospital in Egypt 
(Ashour et al. 2015). When the extracellular enzyme 
production potential of Candida isolates investigated 
in this study was related to their fluconazole resistance 
pattern, it was noted that roughly half of these enzyme-
producing isolates (40–46%) were resistant to flucona-
zole (Table III). The previous reports demonstrated that 
fluconazole resistance was associated with the acquisi-
tion of superior virulence traits by Candida spp., phos-
pholipase and proteinases secretion being among these 
traits (Fekete-Forgacs et al. 2000; Ying and Chunyang 
2012). Biofilms are complex communities of surface-
aggregated microorganisms, trapped in an exopolysac-
charide matrix, and growing on surfaces such as medi-
cal devices (Jabra-Rizk et al. 2004). Almost 68% of the 
isolates tested in the current study were strong biofilm 
producers, the majority of which belonged to C. albi­
cans species (84.2%) (Table III). Kuhn et al. and Hasan 
et al. showed that C. albicans produces quantitatively 
more biofilms compared with the non-albicans Can­
dida isolates (Kuhn et al. 2002; Hasan et al. 2009). Scan-
ning electron microscopy studies on biofilm architec-
tures succeeded in relating the strength and integrity of 
these biofilms to the higher number of hyphal elements 
in C. albicans than in the other species (Tellapragada 
et al. 2014). The fluconazole resistance was detected in 
47.4% of the strong biofilm producers in this study but, 
no statistical correlation between the biofilm formation 
and fluconazole susceptibility was established (p-value 
> 0.05) (data not shown).
Since the treatment of candiduric patients infected 
with fluconazole-resistant Candida spp. with fluconazole 
alone is not an available option for health practitioners 
anymore, the combination of fluconazole with non-anti-
fungal agents has been explored to increase the suscep-
tibility of fluconazole-resistant Candida spp. (da Silva 
et al. 2013; Li et al. 2015; Jia et al. 2016). Some of the 
antibiotic derivatives, such as aminoglycoside analogs 
obtained by structural modifications of kanamycin A 
and B, tobramycin, and gentamicin were reported to 
have antifungal activities and to synergize with azoles 
against Candida spp. (Lu et al. 2018). However, studies 
emphasizing the sensitizing effect of amikacin on flu-
conazole against drug-resistant Candida spp. are lacking 
in the literature. In the present study, we investigated 
the antibiotic resistance-modifying activity of amikacin 
against 12 fluconazole-resistant Candida spp. isolates. 
Although amikacin showed no antifungal activity (it 
didn’t cause any inhibition of the growth of Candida 
isolates at the concentrations exceeding 4,000 µg/ml), it 
potentially sensitized 91.7% of the isolates. The MIC of 
fluconazole in the presence of amikacin (4,000 µg/ml) 
against the majority of resistant C. albicans decreased 
from 1,024 μg/ml to 4 μg/ml, against C. glabrata from 
1,024 μg/ml to 32 μg/ml, and against C. tropicalis as well 
as C. famata the value of the MIC against fluconazole 
dropped from 128 μg/ml to 4 μg/ml (Table V). In their 
study, Lu et al. speculated that gentamicin/flucona-
zole synergism could be mediated by suppressing the 
efflux pumps of C. albicans (Lu et al. 2018). To test this 
hypothesis and to give an insight into the mechanism 
of amikacin sensitization of Candida to fluconazole, the 
rhodamine efflux assay in the absence and presence of 
amikacin (4,000 µg/ml), was performed on the three 
Fig. 4. Percentage of reduction in the rhodamine fluorescence 
intensity after 120 minutes of amikacin (4,000 µg/ml) treatment of 
C6, C21 and C8 Candida isolates.
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isolates; two isolates of C. albicans and one C. glabrata 
(Fig. 1–3). Amikacin suppressed the efflux pumps of 
resistant C. albicans isolates, C6 and C21, with percent-
ages of reduction in the fluorescence intensity of 8.9% 
after 120  minutes of contact (Fig. 4). The inhibiting 
effect of amikacin on the function of efflux pumps of 
C. glabrata isolate was not noticeable when compared to 
the control samples indicating that the impact of ami-
kacin might be strain-dependent (Fig. 4).
Further confirmation on the sensitizing effect of 
amikacin was investigated by quantifying the gene 
expression level of three genes responsible for the flu-
conazole efflux which are CDR1, CDR2 (belonging to 
ATP-binding cassette, ABC transporter), and MDR1 
(a  member of major facilitator superfamily, MFS). 
It was done using the quantitative RT-PCR for two 
selected fluconazole-resistant C. albicans isolates, C6 
and C21 (Fig. 5A and 5B). The levels of expression of 
the housekeeping gene ACT1 did not change after treat-
ment of the cells with 4,000 µg/ml of amikacin. It indi-
cated that vital cellular functions were not impaired by 
amikacin treatment. However, amikacin exerted a sig-
nificant inhibitory effect (p-value < 0.0001) on the genes 
encoding the multidrug efflux pumps. The expression 
of the CDR1, MDR1 and CDR2 genes was downregu-
lated in C. albicans isolate C6 with reduction equivalent 
to 89.4, 61.0, and 42.1%, respectively (Fig. 5A). While 
in C. albicans isolate C21, amikacin downregulated the 
expression of CDR2 and MDR1 by 94% and 43.5%, 
respectively (Fig. 5B). In conclusion, amikacin restored 
the fluconazole antifungal activity against resistant Can­
dida spp. isolates. The putative mechanism of this sen-
sitizing effect of amikacin may be the suppression of 
multidrug efflux pumps. Taken together, these findings 
indicate that amikacin may be regarded as a potential 
sensitizer of Candida isolates to fluconazole that can 
be used in combination in the treatment of candiduria 
with a higher efficiency or at lower administration 
doses. Further in vivo and clinical studies are neces-
sitated to consolidate these conclusions.
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